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In his recent perspective entitled Dengue: the Syndromic
Basis to Pathogenesis Research, Inutility of the 2009 WHO
Case Definition, Halstead expresses concern that adoption
of the 2009 World Health Organization (WHO) classification
scheme will compromise the “analytic clarity needed to
understand mechanisms underlying dengue pathophysiology,
pathogenesis, treatment, and therapeutics.”1 Leaving aside
the important issue of how best to resolve the long running
and convoluted debate on dengue case definitions and classi-
fication, two important misconceptions need to be addressed.
First, rather than being a research tool, the 2009 WHO
dengue classification scheme is primarily intended to be used
by clinicians and public health specialists engaged in dealing
with the ever-expanding global pandemic of dengue disease.2,3
The main objectives of the classification scheme are to
improve case management by timely identification of severe
or potentially severe cases, and to ensure that scarce resources
are directed towards those most in need. The simplicity and
sensitivity of the classification scheme should enable the
complete clinical spectrum of dengue to be captured by sur-
veillance systems and enhance the comparability of epidemi-
ologic data gathered over time from different countries and
regions. If, in addition, the new system provides a valid frame-
work for scientific research on dengue pathogenesis, this
feature should be regarded as a bonus.
The limitations of the 1997 WHO classification scheme of
dengue fever (DF) and dengue hemorrhagic fever (DHF)
grades I, II, III, and IV (grades III and IV being referred to
collectively as dengue shock syndrome [DSS]) with respect to
clinical case management have long been a focus of discus-
sion.4–7 One established dogma has been that DHF/DSS
equates to severe dengue disease, and DF is mild. However,
from a number of studies, it has become clear that a signifi-
cant proportion of clinically severe cases, including patients
with hypovolemic shock caused by plasma leakage, fall within
the DF classification.8–11 The complex nature of the 1997
classification system, the need for frequent laboratory testing
of hematologic parameters, the requirement for all four DHF
criteria to be fulfilled even if shock is present, and the fact
that the supporting evidence for DHF is often identified only
during the recovery phase of the illness are among the factors
contributing to this paradox. Conversely, many cases that ful-
fill all the requirements for a diagnosis of DHF can be conser-
vatively managed and require little or no intervention.9
Recognizing these difficulties, a number of countries devel-
oped local adaptations to the 1997 case classification, intro-
ducing novel categories that were deemed to reflect clinical
disease patterns not captured by the scheme.12–14 Conse-
quently, the classification of dengue became fragmented and
epidemiologic comparisons within and between countries
became almost impossible.
As acknowledged in his perspective, the new 2009 classifi-
cation presents significant improvements over the DF/DHF/
DSS system in two key areas: 1) it reflects disease severity in
real time, and 2) it enables identification of a higher propor-
tion of clinically severe cases.15–18 However, as is also pointed
out, concerns have been raised regarding the possibility that
the recommendation to admit all patients with dengue with
warning signs might increase the total volume of admissions
and adversely affect the quality of care given to hospitalized
case-patients.19 In fact, although the warning signs included in
the 2009 scheme were primarily derived from recommenda-
tions by an expert panel of experienced clinicians, rather than
resulting directly from a formal evidence base,20 it is unlikely
that many doctors working in dengue-endemic areas would
be comfortable managing dengue patients with persistent
vomiting, pleural effusions or ascites, and mucosal bleeding
at home. Additionally, many of the warning signs recom-
mended as criteria for hospital admission were already present
in the 1997 guidelines (acute abdominal pain, restlessness or
lethargy, a decrease in the platelet count concurrent with an
increase in the hematocrit).21 However, after introduction of
any new system, it is important that on-going review and
evaluation are integrated into the structure of change. Several
large multicenter and multinational studies are in progress
and are looking at warning signs that may be associated with
development of severe disease or may predict the need
for hospitalization (ClinicalTrials.gov: NCT01421732 and
NCT01550016), with the eventual aim to introduce amend-
ments to the 2009 classification if supported by evidence from
these prospective studies.
Second, Halstead indicates that the DF/DHF/DSS classifi-
cation system remains useful in the context of current dengue
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research to understand disease pathogenesis and pathophysi-
ology. Undoubtedly, significant scientific advances were
made in the 1960s and 1970s after recognition of dengue virus
infection as the cause of the severe new disease that emerged
across several major cities in Asia at that time; much of our
current understanding of pathogenesis in primary and second-
ary dengue infections stems from that early pioneering
work.22–27 Unfortunately, however, we must also recognize
that we are no nearer to elucidating the mechanisms respon-
sible for the microvascular derangements that are the hall-
mark of severe disease,28–30 or to understanding the immune
correlates of protection,31 than we were more than 40 years
ago. Another long-established dogma that may have contrib-
uted to this lack of progress is the belief that DF and DHF are
two separate disease entities with distinct clinical characteris-
tics. Careful observational studies now suggest that the major
clinical manifestations (altered vascular permeability, throm-
bocytopenia, coagulation derangements, hepatic dysfunction)
show considerable overlap between the two syndromes, and
indicate that dengue virus infection disrupts a number of dif-
ferent physiologic systems to varying degrees in individual
patients, influenced by host and viral factors, with the relative
prominence of the resulting abnormalities determining the
final clinical phenotype.8,32–35 Thus, a spectrum of disease
exists rather than two distinct entities, and it is crucial that
this spectrum is recognized if pathogenesis research is to
move forward in the 21st century.
Halstead is concerned that “if in the future pathogenesis
research is based upon clinical responses included in severe
dengue such patients will exhibit an admixture of dengue
disease syndromes.” We share his concern that great care is
needed when defining clinical groups for comparisons in
pathogenesis studies. However, we would argue that
although patients fulfilling the necessary criteria for DHF or
DSS form reasonably well-defined groups, the DF category
is heterogeneous and includes patients with significant vas-
cular leakage and/or bleeding who fail to fulfill all criteria
for DHF and are therefore classified as having DF by
default.8,9 The resulting diagnostic categories are not mutu-
ally exclusive and interpretation of experimental data is
compromised. In addition, because factors (viral or host)
that contribute to the final phenotype may be different for
particular characteristics such as vascular leakage, bleeding,
or liver dysfunction, it is only by using much stricter defini-
tions of these phenotypes that we are likely to be successful
in teasing out the underlying mechanisms.
Although designed primarily for use as a clinical tool, the
WHO 2009 classification does enable severe dengue cases
to be differentiated into three specific sub-categories (severe
vascular leakage, severe bleeding, and severe organ dysfunc-
tion) to look at pathogenesis in a more focused way. Two
novel susceptibility loci associated with DSS have already
been identified by use of this method.36 However, further
refinement is needed, and we strongly advocate that the
dengue research community should work together to develop
international standards for the detailed discrimination of clin-
ical phenotypes for use in pathogenesis studies and/or thera-
peutic intervention trials. For example, an internationally
agreed system that defines the minimum dataset required to
make an informed evaluation of the severity of vascular leak-
age in an individual patient, potentially enabling a score to
be assigned to facilitate comparisons within and between
research studies, would be invaluable to the research commu-
nity. Similarly development of a systematic approach to defin-
ing the etiology and severity of bleeding manifestations or
hepatic dysfunction would be a major step forward. To reduce
the selection and information bias inherent in retrospective
data collection, we also urge that pathogenesis studies should
be designed to collect data prospectively from well-defined
study populations comprising the full spectrum of dengue
disease, rather than relying on potentially incomplete infor-
mation extracted from the clinical medical records of selected
patient groups.
Finally, it is important to stress that case definition and
case classification serve different purposes and should not
be conflated into a single concept. Typically, a case definition
is used for discovery, epidemiologic, or diagnostic purposes,
usually in the absence of confirmatory laboratory tests, but
case classification separates patients into different disease
categories based on predefined criteria. In the WHO 2009
guidelines, the criteria for making a clinical diagnosis of
dengue remain virtually unchanged, with only minor modifi-
cations from those used to define DF in the 1997 guidelines,
but classification into disease categories has been substan-
tially revised and is now based on clinical severity rather than
a syndromic approach.
In conclusion, dengue is a complex disease. Establishing
change is always difficult, but the need for a clinically rele-
vant, easy to apply case classification is beyond question. Such
a classification scheme needs to reflect the contemporary
epidemiology of the disease, be able to assess severity in real
time, and be globally harmonized. The 1997 WHO scheme
was too complicated to use in clinical or public health settings,
yet was not sufficiently precise for detailed pathogenesis
studies. The 2009 WHO classification, based on prospectively
collected evidence and with on-going validation studies
involving more than 12,000 patients in 12 countries across
Asia and the Americas, brings clarity, clinical and epidemio-
logical utility, and the potential for development of more pre-
cise definitions of clinical phenotype for pathogenesis studies.
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